1. Updates on Anti-VEGF Therapy: Improving Durability and Predicting Response

3. Introduction

4. Brolucizumab: Molecular Characteristics

5. Differences Between Anti-VEGF Agents Used for the Treatment of nAMD

6. HAWK and HARRIER Trial Design

7. HAWK/HARRIER Trial Design: Disease Activity Assessment

8. Brolucizumab Met Primary Endpoint of Noninferiority in Change in BCVA From Baseline to Week 48 with 57% and 52% of Patients Maintained on a q12w Dosing Interval

9. Significantly Fewer Patients on Brolucizumab Had IRF and/or SRF at Week 16 and Week 48

10. Brolucizumab Achieved Superior Reductions in CST vs Aflibercept at End of Matched (Week 16) and Maintenance (Week 48) Phases

11. Therapeutic Response Criteria

12. VIEW 1/2 Results: All Aflibercept Groups Were Noninferior to Monthly Ranibizumab

13. HARBOR Results: Mean BVCA Improvements Clinically Meaningful in All Ranibizumab Groups at 24 Months

14. Fewer Patients on Brolucizumab Had Sub-RPE Fluid

15. Alleviating the Burden/Enhancing the Efficacy

16. Significantly Fewer Brolucizumab Patients Had Disease Activity at the End of the Matched Phase (Week 16)

17. Quantitative vs Qualitative Parameters

18. Unanswered Questions: Future Studies

19. HAWK/HARRIER: Predictability Data

20. HAWK/HARRIER: Primary and Sensitivity Analyses

21. Conclusions

22. Abbreviations

23. Abbreviations (cont)